Phar­ma­Mar’s late-stage test of Zep­syre (lur­binecte­din) has flunked the pri­ma­ry end­point on pro­gres­sion-free sur­vival for plat­inum-re­sis­tant ovar­i­an can­cer pa­tients. And the news tanked the Span­ish biotech’s share price, which plunged 32% on Fri­day as in­vestors re­treat­ed in the wake of the fail­ure.

Phar­ma­Mar had po­si­tioned the drug against topote­can or PLD (li­po­so­mal dox­oru­bicin), but re­searchers say that the PFS was the same. They did spot­light an im­proved safe­ty pro­file, though.

The drug in­hibits an en­zyme called RNA poly­merase II and is in Phase III for non-small cell lung can­cer as well as a Phase II for metasta­t­ic breast can­cer.

Phar­ma­Mar has been go­ing through a tough stretch, with the CHMP vot­ing against an ap­proval for their mul­ti­ple myelo­ma drug Ap­lidin last De­cem­ber. Its mar­ket cap start­ed the day at $389 mil­lion.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended nine drugs for approval this week while also giving thumbs up for six expanded indications, including Novo Nordisk’s approved obesity medication Wegovy for younger people. Wegovy is already approved as an obesity treatment in the EU for adults, and the new indication would allow prescriptions for adolescents aged 12 and older.

RNA biotech GreenLight Biosciences has been handed an offer for potential acquisition.

GreenLight said in a release that it has received a non-binding “indication of interest” from Fall Line Endurance Fund to acquire GreenLight’s capital stock for $0.60 per share in cash. The release said any potential agreement between the two parties would depend on certain conditions.

Through a special committee, the biotech will evaluate the offer but added there’s no certainty a deal will go forward. GreenLight will also not make any more announcements until a deal comes through or “otherwise determines” a statement is necessary.

A public T cell biotech’s chief executive has decided to leave the company.

TScan Therapeutics said Friday morning that CEO David Southwell stepped down earlier this week, leaving both his chief executive and board member roles. Filling in is Gavin MacBeath, the company’s CSO and COO. He became the acting CEO on Tuesday, and will continue to remain CSO and COO, TScan’s announcement read.

The German life science group Sartorius will be picking up French contract manufacturer Polyplus for the price of €2.4 billion, or $2.6 billion.

On Friday, Sartorius announced the acquisition through its French subgroup, Sartorius Stedim Biotech, which will be acquiring Polyplus from private investors ARCHIMED and WP GG Holdings IV. Polyplus has 270 employees and produces materials and components that go into making viral vectors that are used in cell and gene therapies. This includes DNA/RNA reagents as well as plasmid DNA. Polyplus has locations in France, Belgium, China and the US.